Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: Findings from the Women's Health Initiative Observational Study

Menopause

Volumn 21, Issue 3, 2014, Pages 260-266

  Shufelt, Chrisandra L ^a   Merz, C Noel Bairey ^a   Prentice, Ross L ^b   Pettinger, Mary B ^b   Rossouw, Jacques E ^c   Aroda, Vanita R ^d   Kaunitz, Andrew M ^e   Lakshminarayan, Kamakshi ^f   Martin, Lisa W ^g   Phillips, Lawrence S ^h,i   Manson, Joann E ^j  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d MEDSTAR RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^h ATLANTA VA MEDICAL CENTER   (United States)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

Cardiovascular disease; Menopause hormone therapy; Stroke

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG FORMULATION; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MIDDLE AGED; OBSERVATIONAL STUDY; POSTMENOPAUSE; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR; WOMEN'S HEALTH;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MIDDLE AGED; MORTALITY; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; STROKE; UNITED STATES; WOMEN'S HEALTH;

EID: 84896734336     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e31829a64f9     Document Type: Article

References (21)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
2. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701-1712.
3. The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242-255.
4. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Committee Opinion No. 420, November 2008: hormone therapy and heart disease. Obstet Gynecol 2008;112: 1189-1192.
5. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(suppl 1):s1-s66.
6. Lacut K, Oger E, Le Gal G, et al. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb Haemost 2003;90:124-131.
7. Iegura B, Guic-Salobir B, webextjen M, Keber I. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause 2006;13:643-650.
8. Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17A-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol 1985;152:1099-1106.
9. Brosnan JF, Sheppard BL, Norris LA. Haemostatic activation in postmenopausal women taking low-dose hormone therapy: less effect with transdermal administration? Thromb Haemost 2007;97:558-565.
10. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-365.
11. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
12. Bennink HJ. Reprint of Are all estrogens the same? Maturitas 2008;61: 195-201.
13. Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982;144:511-518.
14. Shrank W, Patrick A, Alan Brookhart M. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med 2011;26:546-550.
15. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998;19:61-109.
16. Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008; 168:861-866.
17. Renoux C, Dell'Aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519.
18. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477.
19. ELITE: Early versus Late Intervention Trial with Estrogen, 2005. Available at: http://clinicaltrials.gov/show/NCT00114517. Accessed October 25, 2012.
20. Harman SM, Brinton EA, Cedars M, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005;8:3-12.
21. Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005;162:404-414.